- Home
- LVTX vs RDI Comparison
LVTX vs RDI Comparison
Compare LVTX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- RDI
- Stock Information
- Founded
- LVTX 2016
- RDI 1937
- Country
- LVTX Netherlands
- RDI United States
- Employees
- LVTX N/A
- RDI N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- LVTX Health Care
- RDI Consumer Discretionary
- Exchange
- LVTX Nasdaq
- RDI Nasdaq
- Market Cap
- LVTX 33.9M
- RDI 30.6M
- IPO Year
- LVTX 2021
- RDI N/A
- Fundamental
- Price
- LVTX $1.37
- RDI $1.28
- Analyst Decision
- LVTX Hold
- RDI Hold
- Analyst Count
- LVTX 3
- RDI 1
- Target Price
- LVTX $1.75
- RDI $2.40
- AVG Volume (30 Days)
- LVTX 15.1K
- RDI 28.2K
- Earning Date
- LVTX 08-19-2025
- RDI 08-13-2025
- Dividend Yield
- LVTX N/A
- RDI N/A
- EPS Growth
- LVTX N/A
- RDI N/A
- EPS
- LVTX N/A
- RDI N/A
- Revenue
- LVTX $4,990,000.00
- RDI $205,644,000.00
- Revenue This Year
- LVTX N/A
- RDI $7.47
- Revenue Next Year
- LVTX N/A
- RDI $13.22
- P/E Ratio
- LVTX N/A
- RDI N/A
- Revenue Growth
- LVTX N/A
- RDI N/A
- 52 Week Low
- LVTX $0.85
- RDI $1.17
- 52 Week High
- LVTX $2.39
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- LVTX 61.35
- RDI 42.51
- Support Level
- LVTX $1.27
- RDI $1.23
- Resistance Level
- LVTX $1.33
- RDI $1.37
- Average True Range (ATR)
- LVTX 0.04
- RDI 0.06
- MACD
- LVTX 0.00
- RDI -0.01
- Stochastic Oscillator
- LVTX 89.29
- RDI 25.10
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.